Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes

Allison L. O’Kell1, Timothy J. Garrett2, Clive Wasserfall2 & Mark A. Atkinson2

While predominant as a disease entity, knowledge voids exist regarding the pathogenesis of canine diabetes. To test the hypothesis that diabetic dogs have similar metabolomic perturbations to humans with type 1 diabetes (T1D), we analyzed serum metabolomic profiles of breed- and body weight-matched, diabetic (n = 6) and healthy (n = 6) dogs by liquid chromatography-mass spectrometry (LC-MS) profiling. We report distinct clustering of diabetic and control groups based on heat map analysis of known and unknown metabolites. Random forest classification identified 5/6 dogs per group correctly with overall out of bag error rate = 16.7%. Diabetic dogs demonstrated significant upregulation of glycolysis/gluconeogenesis intermediates (e.g., glucose/fructose, C6H12O6, keto-hexose, deoxy-hexose, (P < 0.01)), with significant downregulation of tryptophan metabolism metabolites (e.g., picolinic acid, indoxyl sulfate, anthranilate, (P < 0.01)). Multiple amino acids (AA), AA metabolites, and bile acids were also significantly lower in diabetic versus healthy dogs (P < 0.05) with the exception of the branched chain AA valine, which was elevated in diabetic animals (P < 0.05). Metabolomic profiles in diabetic versus healthy dogs shared similarities with those reported in human T1D (e.g., alterations in glycolysis/gluconeogenesis metabolites, bile acids, and elevated branched chain AA). Further studies are warranted to evaluate the utility of canine diabetes to provide novel mechanistic insights to the human disorder.

Type 1 diabetes (T1D) is characterized by insulin deficiency and resulting dysglycemia1. Recently, metabolomic analyses have been used to study metabolic changes in T1D patients prior to autoantibody (AAb) development2, associated with AAb seroconversion3, as well as with symptomatic T1D and glycemic control4–6. Specifically, metabolomic alterations documented prior to AAb development in children that later developed T1D include decreased succinic acid, phosphatidylcholine, and citric acid at birth alongside increased pro-inflammatory lysophosphatidylcholine months prior to seroconversion2. AAb positivity is associated with low methionine and hydroxyproline, with high odd-chain triglycerides and polyunsaturated fatty acids (FA) containing phospholipids3. Beyond this, T1D patients with poor glycemic control demonstrate decreased glycolytic metabolites and elevated carbohydrate metabolites, branched chain amino acids (AA), short chain FA, and ketoacids4. Interestingly, many of these metabolic perturbations are also present in T1D patients with good glycemic control5.

Canine diabetes has multiple parallels to human T1D, including a requirement for lifelong insulin therapy in most cases, the development of ketoacidosis at diagnosis or during therapy6, and a suspected role for autoimmunity7,8. Increased levels of glucose, triglycerides, non-esterified FA, cholesterol, ketones, acetate, and β-hydroxybutyrate have been reported in diabetic dogs8. Further research is required to determine the potential for canines with diabetes to be used as an alternative animal model of human T1D9, and if metabolomic analysis may identify novel biomarkers of the disease. While metabolomic profiles have been studied in healthy dogs10,11 and in several disease states, including inflammatory bowel disease12 and degenerative valvular disease13.
information from an untargeted metabolomics assessment of diabetic dogs is lacking. With this study, we evaluated the metabolomic profiles of fasted versus healthy control dogs, and hypothesized that diabetic dogs have metabolomic perturbations similar to those reported in human T1D patients, including alterations in carbohydrates, branched-chain AA and FA.

Materials and Methods

Study approval and enrollment. The study was approved by the University of Florida (UF) Institutional Animal Care and Use Committee (#201609360) and the Veterinary Hospital Research Review Committee. All experiments were performed in accordance with relevant guidelines and regulations. All dog owners provided written informed consent prior to study enrollment. Dogs with naturally occurring diabetes (n = 6) and control dogs (n = 6) were recruited from the hospital population at the UF Small Animal Hospital. Diabetes was diagnosed prior to study enrollment based on clinical signs (polyuria, polydipsia) in combination with persistent hyperglycemia and glucosuria. Diabetic dogs were included if they were >1 year of age with body weight >5 kg, were fasted for a minimum of 12 hours, and if female, were spayed prior to diagnosis of diabetes. Control dogs were deemed healthy based on history and physical exam findings. Control dogs were breed matched to diabetic dogs when possible, and were included if they were >1 year of age with body weight >5 kg, received no medications other than monthly flea/tick/heartworm preventatives, and were fasted for a minimum of 12 hours. All dogs were housed with their owners aside from their visit to the Small Animal Hospital.

Sample collection. Time of blood collection was based on patient availability, but all blood samples were collected between 8 am and 4 pm. Blood was collected using a needle and syringe by routine venipuncture and allotted into red top vacutainer tubes containing clot activator. Serum was separated within 30 min of collection and frozen immediately at −80 °C.

Metabolite extraction. Metabolite extraction and analysis from serum was performed as previously described\textsuperscript{15,16}. Briefly, 100 μL serum aliquots were prepared, and 800 μL of 8:1:1 acetonitrile:methanol:acetone was added to precipitate the proteins. The samples were allowed to cool on ice for 30 minutes before centrifugation to pellet the protein. The supernatant (750 μL) was transferred to a new microcentrifuge tube and dried under a gentle stream of nitrogen. The dried sample was reconstituted in 100 μL of 0.1% formic acid in water for liquid chromatography-mass spectrometry (LC-MS) analysis. LC-MS profiling was performed using a Thermo Q-Exactive Orbitrap mass spectrometer (mass resolution 35,000 at m/z 200) with Dionex UHPLC (ultra-high performance liquid chromatography) and autosampler. Samples were analyzed in a positive and negative heated electrospray ionization as separate injections.

Metabolite analysis. MZmine\textsuperscript{17} was used to align, gap-fill, and identify metabolites across the sample set. Known metabolites were identified by matching to an internal retention time library, except in the case of lipids which were identified by fragmentation pathways from MS/MS. Random forest was used to evaluate the classification performance of metabolomics. Analyses were performed using Metaboanalyst 3.0, an open source R-based program specifically designed for metabolomics\textsuperscript{18}. Values not present in 80% of the data were removed from analysis. Missing values were imputed using k-nearest neighbor, and the data was interquartile range filtered, sum normalized, log2 transformed and autoscaled. All statistical analyses were performed on the combined positive ion and negative ion data sets.

Statistics. Patient characteristics (Table 1) were compared using Mann-Whitney or Fisher’s exact test via GraphPad Prism software v6. Metabolites were compared across the two groups via two-sided t-test, and a heatmap of significantly different features was generated to identify clustering metabolites. P < 0.05 was considered significant.

| Group          | Breed                  | Age (years) | Median Age (years) | Weight (kg) | Median Weight (kg) | Sex\textsuperscript{a} | Duration since diagnosis of diabetes (months) | Median Disease Duration (months) |
|----------------|------------------------|-------------|--------------------|-------------|--------------------|------------------------|------------------------------------------|----------------------------------|
| Diabetic       | Dachshund              | 6.5         | 9.75               | 7.9         | 18.8               | SF                     | 1.5                                      | 4.75                             |
|                | Dachshund              | 13          |                     | 6.9         |                    | SF                     | 1                                       | N/A                              |
|                | Miniature schnauzer    | 9           |                     | 9.5         |                    | NM                     | 8                                       | N/A                              |
|                | Labrador retriever     | 13.5        |                     | 28.4        |                    | SF                     | 11                                      | N/A                              |
|                | Labrador retriever     | 10.5        |                     | 32.5        |                    | NM                     | 11                                      | N/A                              |
|                | Mix (Labrador retriever mix) | 1.3      |                     | 28.1        |                    | NM                     | 1                                       | N/A                              |
| Healthy        | Dachshund              | 4           | 5.5                | 8.8         | 19.75              | SF                     | N/A                                      | N/A                              |
|                | Dachshund              | 11          |                     | 5.2         |                    | SF                     | N/A                                      | N/A                              |
|                | Miniature schnauzer    | 2           |                     | 6.6         |                    | SF                     | N/A                                      | N/A                              |
|                | Labrador retriever     | 7           |                     | 31.8        |                    | SF                     | N/A                                      | N/A                              |
|                | Labrador retriever     | 4           |                     | 43.2        |                    | NM                     | N/A                                      | N/A                              |
|                | Flat coated retriever  | 8           |                     | 30.7        |                    | NM                     | N/A                                      | N/A                              |

Table 1. Patient Characteristics. SF = spayed female; NM = neutered male.
Data availability. The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Results

Age (P = 0.29), body weight (P = 0.99) and sex distribution (P = 1.0) were comparable for diabetic and control groups (Table 1). For diabetic dogs, the median duration from diagnosis was 4.75 months (range: 1–11 months). At the time of sample collection, all diabetic dogs were receiving treatment with exogenous insulin but were suspected to have poorly controlled diabetes based on a combination of continued clinical signs of diabetes and the results of blood and/or urine analysis. None of the enrolled animals had ketoacidosis. Controls were breed-matched to diabetic dogs in all but one case (Table 1).

Two hundred known metabolites were detected in positive and negative ion modes from the extracted serum samples. A heat map of known metabolites that differed significantly between diabetic and healthy dogs indicated clustering of the two cohorts (Fig. 1a). A similar analysis of all detected (unknown and known) metabolites not only enabled classifications based on the entire metabolome, but also improved clustering (Fig. 1b). The top 50 metabolites that differed significantly between groups are shown in Fig. 1b. These data demonstrate the ability of metabolomics to classify diabetic and non-diabetic canines.

The known metabolites identified are categorized by class and/or pathway, direction of change, and fold change in diabetic animals as compared to controls (Table 2). As expected, glycolysis/gluconeogenesis intermediates and sugars were significantly upregulated in the diabetic group, while concentrations of metabolites involved in tryptophan metabolism were downregulated (Table 2). Multiple AA and AA metabolites were significantly lower in the diabetic group, including proline, methionine, histidine, glutamine, and asparagine, while the branched chain AA, valine, was higher. The primary and secondary bile acids, taurochenodeoxycholic acid, taurodeoxycholic acid and tauroursodeoxycholic acid, were significantly lower in diabetic dogs. The lipids lysophosphatidylethanolamine and butyrobetaine were lower in the diabetic group, while 3-hydroxydecanoic acid was higher versus control dogs.

Random forest classification showed excellent prediction of group, with 5/6 animals from each group identified correctly and a 16.7% out of bag (OOB) error rate (Table 3). The healthy control dog misclassified to the diabetic group by this method was confirmed to be normoglycemic in both a fasted and fed state 3 months following study enrollment. The random forest importance plot identified 15 metabolites key in classifying the data, with anthranilate, glucose, glucosamine, and lysophosphatidylethanolamine having the most influence in classification (Fig. 2).

Discussion

In this study using an untargeted metabolomic evaluation, we found that the metabolomic profiles differed significantly among fasted diabetic and healthy dogs, with clear clustering of the groups using known and unknown
| Class/Pathway and Metabolites                  | p-value    | Fold change direction (↑ or ↓) and magnitude |
|----------------------------------------------|------------|---------------------------------------------|
| **Glycolysis/gluconeogenesis intermediates** |            |                                             |
| Glucose/Fructose                             | 0.001205   | ↑ 1.36                                      |
| Glucose/Fructose (Cl adduct)                 | 0.001314   | ↑ 1.36                                      |
| **Aminosugar and nucleotide sugar metabolism** |            |                                             |
| Glucuronic acid                              | 0.00078    | ↑ 1.42                                      |
| Glucosamine/mannosamine                      | 0.000371   | ↑ 1.88                                      |
| **Sugars**                                   |            |                                             |
| C\(_6\)H\(_{12}\)O\(_6\)                    | 0.002526   | ↑ 1.50                                      |
| N-acetyl-hexosamine                          | 0.0003124  | ↑ 1.75                                      |
| Keto-hexose                                   | 0.000148   | ↑ 1.86                                      |
| Deoxy-hexose                                  | 0.000615   | ↓ 0.20                                      |
| 2-deoxy-D-galactose                          | 0.000369   | ↓ 0.32                                      |
| Disaccharide                                  | 0.016432   | ↑ 2.15                                      |
| **Dipeptide**                                |            |                                             |
| Carnosine                                     | 0.007063   | ↑ 1.68                                      |
| **Tryptophan metabolism**                    |            |                                             |
| Picolnic acid                                 | 0.004321   | ↓ 0.42                                      |
| Indoxyl sulfate                               | 0.004485   | ↓ 0.16                                      |
| Anthranilate (2-aminobenzoic acid)           | 0.000553   | ↓ 0.38                                      |
| **Organic acid and derivatives**              |            |                                             |
| 5-aminolevulinic acid                         | 0.0002224  | ↓ 0.42                                      |
| Alpha-hydroxyisobutyric acid                  | 0.009782   | ↓ 4.42                                      |
| **Amino Acids and Metabolites**               |            |                                             |
| Proline                                       | 0.007627   | ↓ 0.66                                      |
| N-acetyl-L-aspartic acid                      | 0.000794   | ↓ 0.44                                      |
| N-acetyl-L-aspartic acid (positive ion)       | 0.001863   | ↓ 0.47                                      |
| Methionine                                    | 0.012396   | ↓ 0.58                                      |
| Methionine sulf oxide                         | 0.001815   | ↓ 0.70                                      |
| Valine                                        | 0.012396   | ↑ 1.27                                      |
| Histidine                                     | 0.016368   | ↓ 0.77                                      |
| Glutamine                                     | 0.020218   | ↓ 0.54                                      |
| Creatinine                                    | 0.021156   | ↓ 0.66                                      |
| Asparagine                                    | 0.049261   | ↓ 0.78                                      |
| N-acetyl-L-leucine                            | 0.022766   | ↓ 0.51                                      |
| 3-hydroxyphenylacetic acid                    | 0.006011   | ↓ 0.56                                      |
| N-formylglycine                               | 0.040731   | ↓ 0.74                                      |
| **Bile acids**                                |            |                                             |
| Taurodeoxycholic acid                         | 0.035656   | ↓ 0.07                                      |
| Taurochenodeoxycholic acid                    | 0.043389   | ↓ 0.08                                      |
| Tauroursodeoxycholic acid                     | 0.005472   | ↓ 0.27                                      |
| **Organoheterocyclic compounds**              |            |                                             |
| N-methylnicotinamide                          | 0.007934   | ↓ 0.38                                      |
| **Aldehyde**                                  |            |                                             |
| 5-hydroxymethyl-2-furaldehyde                 | 0.000515   | ↑ 2.03                                      |
| **Benzenoid**                                 |            |                                             |
| Phenethylamine                                | 0.028163   | ↓ 0.80                                      |
| **Lipids**                                    |            |                                             |
| LysoPE 18:1                                   | 0.000226   | ↓ 0.34                                      |
| 3-hydroxydecanoic acid                        | 0.02393    | ↑ 1.72                                      |
| Butyrobetaine                                 | 0.047759   | ↓ 0.77                                      |
| **Microbial origin**                          |            |                                             |
| Citramalate (fatty acid)                      | 0.013703   | ↑ 4.59                                      |
| LL-2,6 diaminohexanediose (Diaminopimelic acid) | 0.049682 | ↓ 0.76                                      |
| **Other Exogenous**                           |            |                                             |
| Tertbutyl adipic acid                         | 0.048648   | ↓ 0.45                                      |
| Hexanesulfonic acid                           | 0.011531   | ↓ 0.13                                      |

Table 2. Significant Metabolites and Pathways in Diabetic Dogs. *↓* indicates downregulation and *↑* indicates upregulation compared with findings in healthy control dogs. Fold change was calculated for diabetic relative to healthy dogs.
metabolite expression. Based on random forest classification, 5/6 (83%) dogs in each group were classified correctly, an excellent result given the small sample size. The healthy dog that was misclassified as a diabetic dog (Miniature Schnauzer, Fig. 1) in this analysis was confirmed to be normoglycemic 3 months following the study. This dog displayed upregulated carnosine and downregulated histidine, N-acetyl-L-leucine, and multiple bile acids (similar to diabetic dogs). Possible reasons for this discrepancy include individual variability in metabolomic profiles, environmental or dietary factors, a yet unidentified pre-diabetic state, or other undiagnosed underlying disease.

Studies examining inter- and intra-individual variability in metabolomic profiles in dogs indicate that dog breed is an important factor in metabolomic profile variance in the non-controlled (i.e. home) environment, along with some influence of gender and body weight. Importantly, in this study, all but two dogs were breed and gender matched and the non-breed matched dogs were body weight matched. The results of this pilot study support future research to expand the scope by increasing the number of dogs examined and implementing a longitudinal design with multiple time points. Moreover, the analytical methods employed have excellent mass accuracy (5 ppm or better) and retention time reproducibility (less than 0.1 min fluctuations), but do not separate all the sugar related species. We also plan to conduct additional studies to identify unknown metabolites with the addition of hydrophilic interaction liquid interaction chromatography (HILIC) to improve separation of sugar related metabolites.

Observed elevations in carbohydrate metabolites and alterations in glycolysis/gluconeogenesis metabolites in diabetic dogs were expected and similar to humans with T1D undergoing insulin therapy. Similarly, the branched chain AA valine was significantly elevated in diabetic dogs; branched chain AA (valine, leucine, isoleucine) have also been documented to be elevated in diabetic dogs and humans prior to and after onset of both T1D and type 2 diabetes (T2D) as well as in diabetic NOD (non-obese diabetic) mice. However, we report lower N-acetyl-L-leucine in diabetic dogs versus controls while isoleucine was not identified as significantly differing between the groups, representing a potential divergence from human T1D or simply a limitation of the small sample size. The AA methionine was lower in diabetic dogs, similar to children who develop islet AAb at an early age but in contrast to human T1D patients undergoing insulin therapy but with poor glycemic control and reported elevations in this AA. Several metabolites in involved in tryptophan metabolism (e.g., anthranilate/2-aminobenzoic acid, picolinic acid, indoxyl sulfate) were lower in diabetic dogs versus healthy controls. This contrasts to reports of increased anthranilic acid in insulin-treated human T1D patients compared to metformin-treated T2D patients and controls without diabetes. Further investigation is needed to determine the implications of these findings in dogs, particularly given the importance of anthranilate in the random forest variable importance plot (Fig. 2a).

Although the dogs in this study were receiving insulin, all were undergoing evaluation for poor diabetes control

| Actual Group | Predicted Group | Class Error* |
|--------------|-----------------|--------------|
| Diabetic     | Healthy         | 0.167        |
| Healthy      | Diabetic        | 0.167        |

Table 3. Random Forest Classification into Healthy or Diabetic Dog Groups. *Overall out of bag (OOB) error rate is 16.7%.

Figure 2. (a) Random forest variable importance plot. Mean decrease accuracy is the measure of the performance of the model without each metabolite. A higher value indicates the importance of that metabolite in predicting group (diabetic vs. healthy). Removal of that metabolite causes the model to lose accuracy in prediction. (b) Box and whisker plots of the top four metabolites from (a). Data was sum normalized, log transformed and autoscaled.
at the time of sample collection. As noted above, some metabolomic alterations in humans with T1D are present in patients regardless of the degree of glycemic control. Additional studies comparing dogs with poor glycemic control versus well-controlled diabetic canines are required to determine if this observation holds true in dogs. Thus, metabolomic profiles of untreated diabetic dogs would be expected to have some similarities to dogs with poorly controlled diabetes, along with elevations in ketoacids. Ketone in dogs has been associated only with very low serum insulin concentrations, and the insulin doses received by dogs enrolled in this study likely were adequate to prevent significant elevations in ketoacids.

Another interesting finding was the upregulation of carnosine in diabetic dogs compared with control dogs. Carnosine has been shown to inhibit the formation of some advanced glycation end products (AGEs) in vitro and to inhibit glucose- induced production of type IV collagen and fibronectin by podocytes in the kidneys. A genetic mutation resulting reduced expression of the carnosinase enzyme that degrades carnosine protects against the development of diabetic nephropathy in human patients. While dogs with experimentally induced and naturally occurring diabetes do develop renal glomerular lesions consistent with diabetic nephropathy, dogs with naturally occurring diabetes do not seem to commonly develop clinically significant diabetic nephropathy. Although this is speculated to be due to the shorter lifespan of dogs and lack of time for significant renal disease pathology to develop, the elevation in carnosine could be relevant. Further study is required to confirm these findings and any relationship to the formation of AGEs in dogs.

Primary and secondary bile acid levels were found to be lower in diabetic dogs, and perturbations in a variety of bile acids have been identified in humans with T1D and T2D. Bile acids have been recognized as having endocrine functions and are involved in glucose homeostasis. Adding to the complexity of bile acid metabolic function is the interplay with the gut microbiota, which has recently been shown to be altered in humans and rodents with diabetes. In the present study, gut microbiota was not evaluated and the cause of the alterations in bile acids is unknown. Given the important role bile acids play in metabolism, additional investigation is warranted.

In sum, we found that the metabolomic profiles of diabetic dogs differ significantly from healthy non-diabetic dogs. To the authors' knowledge, this study represents the first evaluation of metabolomic profiles in diabetic canines. Both similarities to and differences from metabolic perturbations in humans with diabetes were identified. Further research is needed with increased sample size in a longitudinal study design and, potentially, with a standardized diet to confirm the findings reported herein and identify the underlying mechanisms that contribute to these metabolic changes. Many unknowns still exist with respect to the pathogenesis of canine diabetes, and metabolomic alterations may represent important potential biomarkers to detect diabetes in dogs prior to clinical onset. Indeed, the ability to detect the pre-diabetic state may represent a key component to future discovery in this area and to further define the utility of the dog as a potential model of human T1D.

References

1. Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. Lancet 383, 69–82, doi:10.1016/S0140-6736(13)60591-7 (2014).
2. Oresic, M. et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 205, 2975–2984, doi:10.1084/jem.20081800 (2008).
3. Pfleuger, M. et al. Age- and islet autoimmunity-associated differences in amino acid and lipid metabolites in children at risk for type 1 diabetes. Diabetes 60, 2740–2747, doi:10.1123/diabetes.2011-0141 (2011).
4. Dutta, T. et al. Impact of Long-Term Poor and Good Glycemic Control on Metabolomics Alterations in Type 1 Diabetic People. J Clin Endocrinol Metab 101, 1023–1033, doi:10.1210/jc.2015-2640 (2016).
5. Lanza, I. R. et al. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 5, e10538, doi:10.1371/journal.pone.0010538 (2010).
6. Balderas, C. et al. Plasma and urine metabolic fingerprinting of type 1 diabetic children. Electrophoresis 34, 2882–2890, doi:10.1002/elps.201300062 (2013).
7. Nelson, R. W. & Reusch, C. E. Animal models of disease: classification and etiology of diabetes in dogs and cats. J Endocrinol 222, 71–9, doi:10.1530/joe-14-0202 (2014).
8. Davison, L. J., Weenink, S. M., Christie, M. R., Heritage, M. E. & Catchpole, B. Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus. Vet Immunol Immunopathol 126, 83–90, doi:10.1016/j.vetimm.2008.06.016 (2008).
9. Durocher, L. L., Hinchcliff, K. W., DiBartola, S. P. & Johnson, S. E. Acid-base and hormonal abnormalities in dogs with naturally occurring diabetes mellitus. J Am Vet Med Assoc 232, 1310–1320, doi:10.2460/javma.232.9.1310 (2008).
10. O’Kell, A. L. et al. Comparative pathogenesis of autoimmune diabetes in humans, NOD mice, and canines: has a valuable animal model of type 1 diabetes been overlooked? Diabetes 66, 1443–1452 (2017).
11. Lloyd, A. J. et al. Characterisation of the main drivers of intra- and inter- breed variability in the plasma metabolome of dogs. Metabolomics 12, 72, doi:10.1007/s11306-016-9997-6 (2016).
12. Colyer, A., Gilham, M. S., Kamlage, B., Rein, D. & Allaway, D. Identification of intra- and inter-individual metabolite variation in plasma metabolite profiles of cats and dogs. Br J Nutr 106(Suppl 1), S146–149, doi:10.1017/S000711451100081x (2011).
13. Mimamoto, Y. et al. Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease. Gut Microbes 6, 33–47, doi:10.4161/gmic.99490.2014.997612 (2015).
14. Li, Q. et al. Veterinary Medicine and Multi-Omics Research for Future Nutrition Targets: Metabolomics and Transcriptomics of the Common Degenerative Mitral Valve Disease in Dogs. Omics 19, 461–470, doi:10.1089/omi.2015.0057 (2015).
15. Patterson, R. E., Durocq, A. J., McDougall, D. J., Garrett, T. J. & Yost, R. A. Comparison of blood plasma sample preparation methods for combined LC-MS lipidomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 1002, 260–266, doi:10.1016/j.jchromb.2015.08.018 (2015).
16. Liu, H., Garrett, T. J., Tayyari, F. & Gu, L. Profiling the metabolome changes caused by cranberry procyanidins in plasma of female rats using (1) H NMR and UHPLC-Q-Orbitrap-HRMS global metabolomics approaches. Mol Nutr Food Res 59, 2107–2118, doi:10.1002/mnfr.201500236 (2015).
17. Pluskal, T., Castillo, S., Villar-Briones, A. & Oresic, M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 11, 395, doi:10.1186/1471-2105-11-395 (2010).
18. Xie, J. & Wishart, D. S. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis. Curr Protoc Bioinformatics 55, 14.10.11–14.10.91, doi:10.1002/cpbi.11 (2016).
19. Lloyd, A. J. et al. Ultra high performance liquid chromatography-high resolution mass spectrometry plasma lipidomics can distinguish between canine breeds despite uncontrolled environmental variability and non-standardized diets. *Metabolomics* **13**, 15, doi:10.1007/s11306-016-1152-0 (2017).

20. Oresic, M. et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. *J Exp Med* **205**, 2975–2984, doi:10.1084/jem.20081800 (2008).

21. Xu, F. et al. Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics. *J Clin Endocrinol Metab* **98**, E1060–1065, doi:10.1210/jc.2012-4132 (2013).

22. Grapov, D. et al. Diabetes Associated Metabolomic Perturbations in NOD Mice. *Metabolomics* **11**, 425–437, doi:10.1007/s11306-014-0706-2 (2015).

23. Oxenkrug, G., van der Hart, M. & Summergrad, P. Elevated anthranilic acid plasma concentrations in type 1 but not type 2 diabetes mellitus. *Integr Mol Biol* **2**, 365–368, doi:10.15761/immb.1000169 (2015).

24. Duarte, R. et al. Accuracy of serum beta-hydroxybutyrate measurements for the diagnosis of diabetic ketoacidosis in 116 dogs. *J Vet Intern Med* **16**, 411–417 (2002).

25. Hipkiss, A. R. et al. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. *Ann N Y Acad Sci* **854**, 37–53 (1998).

26. Janssen, B. et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. *Diabetes* **54**, 2320–2327 (2005).

27. Steffes, M. W. et al. Diabetic nephropathy in the uninephrectomized dog: microscopic lesions after one year. *Kidney Int* **21**, 721–724 (1982).

28. Jeraj, K., Basgen, J., Hardy, R. M., Osborne, C. A. & Michael, A. F. Immunofluorescence studies of renal basement membranes in dogs with spontaneous diabetes. *Am J Vet Res* **45**, 1162–1165 (1984).

29. Nelson, R. In *Canine and Feline Endocrinology* (eds Feldman, E. C., Nelson, R. W., Reusch, C. E. & Scott-Moncrief, J. C. R.) Ch. 6, 213–257 (Elsevier, 2015).

30. Herring, I. P., Panciera, D. L. & Werre, S. R. Longitudinal prevalence of hypertension, proteinuria, and retinopathy in dogs with spontaneous diabetes mellitus. *Vet Hum Toxicol* **213–257** (Elsevier, 2015).

31. Wewalka, M., Patti, M. E., Barbato, C., Houten, S. M. & Goldfine, A. B. Fasting serum taurine-conjugated bile acids are elevated in dogs with spontaneous diabetes mellitus. *Kidney Int* **854**, 1442–1451, doi:10.1210/jc.2013-3367 (2014).

32. Houten, S. M., Watanabe, M. & Auwerx, J. Endocrine functions of bile acids. *Enboby* **25**, 1419–1425, doi:10.1586/17415925.2006.101009 (2006).

33. Staley, C., Weingarden, A. R., Khoruts, A. & Sadowsky, M. J. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. *Appl Microbiol Biotechnol* **101**, 47–64, doi:10.1007/s00253-016-8006-6 (2017).

34. Tai, N., Wong, F. S. & Wen, L. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. *Rev Endocr Metab Disord* **16**, 55–65, doi:10.1007/s11354-015-9309-0 (2015).

### Acknowledgements
This work was supported by grants from the National Institutes of Health (P01 AI42288) and (U24 DK097209).

### Author Contributions
A.L.O. conceived of the study, collected the data, analyzed and interpreted the data, and wrote the manuscript; T.J.G. conducted the analytical measurements, performed statistical analysis, analyzed and interpreted the data, and wrote the manuscript. C.W. conceived of the study, analyzed and interpreted the data, contributed to the discussion, and reviewed/edited the manuscript; M.A.A. conceived of the study, contributed to discussion and reviewed/edited the manuscript.

### Additional Information

#### Competing Interests:
The authors declare that they have no competing interests.

#### Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access] This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2017